Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns “Hold” Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPHFree Report) in a research report sent to investors on Wednesday morning, Benzinga reports.

Several other analysts also recently commented on AMPH. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an overweight rating and a $60.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of Hold and an average price target of $66.00.

Check Out Our Latest Research Report on Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Stock Down 1.3 %

NASDAQ:AMPH opened at $39.62 on Wednesday. The firm’s 50-day moving average price is $47.31 and its 200-day moving average price is $51.31. The company has a market capitalization of $1.91 billion, a PE ratio of 15.36, a P/E/G ratio of 0.96 and a beta of 0.84. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. Amphastar Pharmaceuticals has a 1-year low of $35.62 and a 1-year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The firm had revenue of $178.11 million for the quarter, compared to analysts’ expectations of $174.90 million. On average, equities analysts predict that Amphastar Pharmaceuticals will post 3.42 EPS for the current fiscal year.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the transaction, the director now owns 21,326 shares in the company, valued at approximately $1,006,160.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,000 shares of company stock worth $660,860. Company insiders own 28.40% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several institutional investors have recently made changes to their positions in AMPH. McGlone Suttner Wealth Management Inc. bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $28,000. Principal Securities Inc. bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $34,000. Point72 Middle East FZE bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $50,000. Ronald Blue Trust Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 821.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock worth $55,000 after purchasing an additional 1,068 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 99.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after purchasing an additional 628 shares during the period. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Further Reading

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.